Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sensation of foreign body08.01.09.002--Not Available
Immunodeficiency10.03.02.0020.000122%Not Available
Bone lesion15.02.04.0160.000035%Not Available
Demyelinating polyneuropathy17.09.04.003; 10.04.10.0070.000035%Not Available
Disease recurrence08.01.03.0500.000489%Not Available
Diverticular perforation07.04.04.0080.000052%Not Available
Obstructive airways disorder22.03.01.0110.000105%Not Available
Psychotic disorder19.03.01.0020.000524%
Hepatic lesion09.01.08.0050.000052%Not Available
Immunosuppression10.03.02.0010.000367%Not Available
Hyperlipidaemia14.08.03.0010.000070%
Pigmentation disorder23.05.03.0010.000035%Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000070%Not Available
Renal impairment20.01.03.0100.001066%Not Available
Lipohypertrophy23.07.01.005; 14.08.04.0090.000035%
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.000035%Not Available
Increased bronchial secretion22.12.01.0020.000035%Not Available
Muscle contracture15.03.05.0240.000077%Not Available
Peripheral arterial occlusive disease24.04.03.0100.000035%Not Available
Haemorrhagic diathesis24.07.01.020; 01.01.03.0030.000070%Not Available
Increased upper airway secretion22.12.03.0070.000087%Not Available
Neutropenic colitis07.08.01.014; 01.02.03.0100.000052%Not Available
Chorioretinopathy06.09.01.0060.000821%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000164%Not Available
Autism spectrum disorder17.03.05.003; 19.22.02.0020.000052%Not Available
Orthostatic intolerance24.06.01.003; 02.11.01.019; 17.05.01.0070.000052%Not Available
Gastrointestinal inflammation07.08.03.0070.000105%Not Available
Osteonecrosis of jaw24.04.05.005; 15.02.04.0100.001940%
Ulcerative keratitis10.02.01.021; 06.04.02.0040.000035%
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.000087%Not Available
The 27th Page    First    Pre   27 28 29 30 31    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene